HER2-Low

Enhertu for people living with HER2-low metastatic breast cancer
We have some amazing news to share with our network today, following an announcement this morning from the Australian Government. People living with HER2-low metastatic breast cancer will, from 1 September 2024, have access to the life-prolonging drug Enhertu (trastuzumab deruxtecan) through the Pharmaceutical Benefits…
Pharmaceutical Benefits Advisory Committee (PBAC) - Enhertu for HER2-low Metastatic Breast Cancer
The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the drug Enhertu (trastuzumab deruxtecan) for people with HER2-low metastatic breast cancer (MBC) to be subsidised on the Pharmaceutical Benefits Scheme (PBS). We now call on the Australian Government to work with the pharmaceutical company to list…

Discussion List